Codexis shares surge 35.43% intraday after Q4 2025 earnings beat, strong 2026 revenue guidance, and Merck tech transfer agreement.

Thursday, Mar 12, 2026 10:23 am ET1min read
CDXS--
Codexis surged 35.43% intraday, driven by Q4 2025 results exceeding expectations (revenue of $38.9M, up 81% YoY, surpassing analyst estimates of $36.82M, and net profit of $9.6M vs. a $10.4M loss in 2024), a 2026 revenue guidance of $72–76M (above market forecasts of $70.8M), and progress in core operations, including a $37.8M technology transfer agreement with Merck and advancements in RNAi applications via its ECO Synthesis platform.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet